Francesco Cavaliere

Summary

Country: Italy

Publications

  1. doi Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O
    F Cavaliere
    Department of Surgery, San Giovanni Hospital, Via dell amba Aradam 9, 00184 Rome, Italy
    Eur J Surg Oncol 37:148-54. 2011
  2. ncbi Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment
    Francesco Cavaliere
    Department of General Surgery and Organ Transplantation, San Camillo Forlanini Hospital, Rome, Italy
    In Vivo 23:441-6. 2009
  3. ncbi 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study
    F Cavaliere
    Surgical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    In Vivo 20:747-50. 2006
  4. ncbi Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis
    Franco Di Filippo
    Regina Elena National Cancer Institute, Rome, Italy
    In Vivo 20:739-42. 2006
  5. ncbi Treatment of peritoneal carcinomatosis with intent to cure
    F Cavaliere
    First Department of Surgical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Surg Oncol 74:41-4. 2000
  6. ncbi Liposomal doxorubicin with and without TNFalpha in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results
    Franco Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    In Vivo 20:735-8. 2006
  7. ncbi Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis
    F Cavaliere
    First Department of Surgical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Eur J Surg Oncol 26:486-91. 2000
  8. ncbi Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome
    Patrizia Ferroni
    Biomarker Discovery and Advanced Technologies BioDAT Laboratory, Scientific Institute for Research, Hospitalization and Health Care IRCCS San Raffaele Pisana, via della Pisana 235, 00163, Rome, Italy
    Anticancer Res 34:1153-61. 2014
  9. ncbi Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 22:97-101. 2003
  10. ncbi Hyperthermic antiblastic perfusion in the treatment of locoregional spreading limb melanoma
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 22:89-95. 2003

Collaborators

Detail Information

Publications26

  1. doi Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O
    F Cavaliere
    Department of Surgery, San Giovanni Hospital, Via dell amba Aradam 9, 00184 Rome, Italy
    Eur J Surg Oncol 37:148-54. 2011
    ....
  2. ncbi Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment
    Francesco Cavaliere
    Department of General Surgery and Organ Transplantation, San Camillo Forlanini Hospital, Rome, Italy
    In Vivo 23:441-6. 2009
    ....
  3. ncbi 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study
    F Cavaliere
    Surgical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    In Vivo 20:747-50. 2006
    ..The patients treated with oxaliplatin were alive and free-of-disease after a 16-month median follow-up...
  4. ncbi Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis
    Franco Di Filippo
    Regina Elena National Cancer Institute, Rome, Italy
    In Vivo 20:739-42. 2006
    ..After eighteen years from its first clinical application, more than 300 patients have been treated. The aim of this study is to clarify two major arguments: the TNFalpha dose and eligibility criteria for patient selection...
  5. ncbi Treatment of peritoneal carcinomatosis with intent to cure
    F Cavaliere
    First Department of Surgical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Surg Oncol 74:41-4. 2000
    ..Low-grade malignant tumors arise in the abdomen, do not infiltrate, and "redistribute" on the peritoneum with no extraregional spreading. In these cases, aggressive surgery combined with localized chemotherapy may provide cure...
  6. ncbi Liposomal doxorubicin with and without TNFalpha in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results
    Franco Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    In Vivo 20:735-8. 2006
    ..The key solution might be the use of liposomal doxorubicin (Caelyx) because the carrier seems to release the drug preferentially in the tumor rather than in the healthy tissue...
  7. ncbi Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis
    F Cavaliere
    First Department of Surgical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Eur J Surg Oncol 26:486-91. 2000
    ..In these cases complete surgical tumour cytoreduction followed by intra- or post-operative regional chemotherapy has curative potential. The aim of this study was to evaluate the outcome for patients treated in this way...
  8. ncbi Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome
    Patrizia Ferroni
    Biomarker Discovery and Advanced Technologies BioDAT Laboratory, Scientific Institute for Research, Hospitalization and Health Care IRCCS San Raffaele Pisana, via della Pisana 235, 00163, Rome, Italy
    Anticancer Res 34:1153-61. 2014
    ..This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC)...
  9. ncbi Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 22:97-101. 2003
    ..Patients with bulky tumor are the best candidate to TNF perfusion, because no differences have been observed in terms of CR in patients with low tumor burden treated with TNF-Melphalan-hyperthermia or Melphalan-hyperthermia...
  10. ncbi Hyperthermic antiblastic perfusion in the treatment of locoregional spreading limb melanoma
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 22:89-95. 2003
    ..009) rates were concerned. Of the tumor-related prognostic factors, the number of lesions (P<0.0014), sex (P<0.04), and the number of disease recurrences (P<0.01) appear to influence overall survival...
  11. ncbi Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy
    In Vivo 23:363-7. 2009
    ..The aim of this paper is to report on the results obtained in 75 patients with limb-threatening STS treated with a low TNFalpha dose and doxorubicin (Dx)...
  12. ncbi TNFa-based isolated hyperthermic limb perfusion (HILP) in the treatment of limb recurrent melanoma: update 16 years after its first clinical application
    F Di Filippo
    Regina Elena National Cancer Institute, Rome, Italy
    J Chemother 16:62-5. 2004
    ..Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFalpha HILP carried out with only 1 mg...
  13. ncbi Squamous and adenosquamous cell carcinomas of the gallbladder
    A Mingoli
    Dept of Surgery Pietro Valdoni, University of Rome La Sapienza, Policlinico Umberto I, Rome, Italy
    J Exp Clin Cancer Res 24:143-50. 2005
    ..In conclusion, an aggressive and radical surgical treatment of advanced squamous and adenosquamous cell gallbladder carcinomas seems to be indicated for their low proclivity to distant spreading...
  14. ncbi Sitilo experience on peritoneal carcinomatosis from colorectal cancer: clinical prognostic features
    F Cavaliere
    Dept of Surgical Oncology, Regina Elena National Cancer Institute of Rome
    J Exp Clin Cancer Res 22:29-33. 2003
    ..Disease-free interval seems to be a powerful prognostic indicator and deserve to be better outlined in further studies...
  15. ncbi [Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology]
    F Cavaliere
    SC Chirurgia Generale A, Polo Oncologico, Istituto Regina Elena, Roma
    Tumori 89:21-3. 2003
    ..In conclusion PCI < or = 10, complete or optimal cytoreduction feasibility and disease-free interval have to be considered for the patients selection to the integrate treatment...
  16. ncbi [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase]
    F Di Filippo
    Polo Oncologico, Istituto Regina Elena, Roma
    Tumori 89:241-3. 2003
    ..The greater effectiveness of trimodality association has to be confirmed by multicentric randomized trials...
  17. ncbi Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study
    O Glehen
    Centre Hospitalo Universitaire Lyon Sud, Pierre Benite, France
    J Clin Oncol 22:3284-92. 2004
    ..New approaches combining cytoreductive surgery and perioperative intraperitoneal chemotherapy suggest improved survival...
  18. ncbi [Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve]
    F Cavaliere
    Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
    Suppl Tumori 4:S119-21. 2005
    ..Peritoneal carcinomatosis patients, that are submitted to integrated treatment, need a peculiar management that is not comparable to any other in the oncological setting and that requires specific competence...
  19. ncbi [Laparoscopic intraperitoneal antiblastic hyperthermic chemoperfusion in the treatment of refractory neoplastic ascites. Preliminary results]
    M Valle
    Azienda Ospedaliera S Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
    Suppl Tumori 4:S122-3. 2005
    ..The authors report 14 cases of peritoneal malignancy, not amenable to peritonectomy due to massive infiltration of the small bowel. The ascites disappeared in all treated cases...
  20. ncbi An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma
    M Deraco
    Dept of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Exp Clin Cancer Res 22:41-5. 2003
    ..CRS + IPHP was proven to be acceptable in terms of morbidity and mortality in patients with PM and suggest a positive impact on outcome. Further prospective controlled studies are warranted to confirm these results...
  21. ncbi An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei
    M Deraco
    Dept of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan Italy
    J Exp Clin Cancer Res 22:35-9. 2003
    ..CRS associated with IPHP permitted complete tumour removal with an acceptable morbidity and mortality in patients with PMP. This study confirms the efficacy of the combined treatment on long-term survival and local disease control...
  22. ncbi [Doxorubicin in antiblastic hyperthermic perfusion in the treatment of advanced soft-tissue sarcoma of the limbs]
    F Di Filippo
    Istituto Nazionale Tumori Regina Elena, Roma
    Suppl Tumori 4:S126-7. 2005
    ..5 degrees C; the conservative surgery was possible in 91% of the cases and mild (grade I and II) toxicity was observed in the perfused limb with high temperature (>41.5 degrees C)...
  23. ncbi Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Rome Italy
    J Exp Clin Cancer Res 22:81-7. 2003
    ..The results above mentioned showed the HAP with doxorubicin and TNFalpha (1 mg) is a very effective neoadjuvant treatment in the multidisciplinary treatment of advanced soft tissue limb sarcoma...
  24. ncbi [Integrated treatment of peritoneal carcinomatosis: preliminary experience]
    B De Rosa
    Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
    Suppl Tumori 4:S117-8. 2005
    ..Two-yr overall survival was 49.1% for all series. Difference in survival evaluating CC 0-1 vs CC 2 patients was statistically significant...
  25. ncbi [Hyperthermic-antiblastic perfusion in the treatment of tumor of the extremities]
    F Di Filippo
    Polo Oncologico Istituto Regina Elena, Struttura Complessa di Chirurgia Generale A di Roma
    Suppl Tumori 1:S35-7. 2002
  26. ncbi Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma
    F Di Filippo
    Regina Elena National Cancer Institute Rome, Italy
    J Chemother 16:66-9. 2004
    ..5 degrees C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases...